PAYX's top line in the third quarter of fiscal 2025 gains from the Management Solutions, and PEO and Insurance Solutions segments.
Vous n'êtes pas connecté
Enzo Biochem revenues decline in second-quarter fiscal 2025. Cost cuts improve margins, but NYSE compliance issues and market slowdown persist.
PAYX's top line in the third quarter of fiscal 2025 gains from the Management Solutions, and PEO and Insurance Solutions segments.
PAYX's top line in the third quarter of fiscal 2025 gains from the Management Solutions, and PEO and Insurance Solutions segments.
CTAS' third-quarter fiscal 2025 organic revenues increase 8.4% year over year on solid segmental sales.
CTAS' third-quarter fiscal 2025 organic revenues increase 8.4% year over year on solid segmental sales.
Chewy (CHWY) delivered earnings and revenue surprises of 33.33% and 1.60%, respectively, for the quarter ended January 2025. Do the numbers hold clues...
Cintas (CTAS) delivered earnings and revenue surprises of 7.62% and 0.53%, respectively, for the quarter ended February 2025. Do the numbers hold...
Cintas (CTAS) delivered earnings and revenue surprises of 7.62% and 0.53%, respectively, for the quarter ended February 2025. Do the numbers hold...
Paychex (PAYX) delivered earnings and revenue surprises of 0.68% and 0.03%, respectively, for the quarter ended February 2025. Do the numbers hold...
Paychex (PAYX) delivered earnings and revenue surprises of 0.68% and 0.03%, respectively, for the quarter ended February 2025. Do the numbers hold...
Verint (VRNT) delivered earnings and revenue surprises of -22.05% and 8.43%, respectively, for the quarter ended January 2025. Do the numbers hold...